Ganstigmine. Chiesi.
作者信息
Johnson Anthony
机构信息
Anthony Johnson Consulting, Durham Close, Sawbridgeworth, Hertfordshire, CM21 0HD, UK.
出版信息
Curr Opin Investig Drugs. 2003 Jul;4(7):868-73.
PMID:14619410
Abstract
Ganstigmine (CHF-2819) is being developed by Chiesi as a potential treatment for neurodegenerative and cognitive disorders. The drug was in phase IIa studies in the US for senile dementia associated with Alzheimer's disease (AD) by mid-2000, and phase IIb trials in AD patients were scheduled for early 2001, with these ongoing in 2002.
摘要
Zotero 插件